Category: Scientific Communications

Madrid, Spain – 24-26 June 2026 “SEALS”: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Efficacy And Safety Of NX210c In Amyotrophic Lateral Sclerosis (ALS) Patients – Preliminary Results Presented by Dr Emilien Bernard, Hospices Civils de Lyon, Coordinating Investigator of SEALS study, during TRICALS Satellite at the ENCALS meeting: insights in recent and upcoming … Continued

Phase II clinical trial evaluating NX210c drug candidate efficacy in ALS patients (“SEALS”): rational and innovative design 

NX210c peptide: a drug candidate to repair the BBB in neurological disorders Chris Greene2, Nicolas Rebergue1, Gwen Fewell3, Supriya Mahajan4, Damir Janigro4, Daniël Dumas5, Philip Kremer5, Juliette Le Douce1, Sébastien Marie1, Yann Godfrin1,6, Annette Janus1, Matthew Campbell2 1Axoltis Pharma, Lyon, France 2Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland 3SynVivo, … Continued

NX210c drug candidate peptide improves motor function and prolongs survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis Liam Beckett2, Irina Belaya3, Jaan Korpikoski2, Katja M. Kanninen3, Merja H. Voutilainen2, Yann Godfrin1,4 1Axoltis Pharma, Lyon, France 2HiLife, University of Helsinki, Helsinki, Finland 3AI Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland … Continued

NX210c drug candidate peptide promotes functional recovery and repair in a rat cervical clip-compression model of spinal cord injury Nayaab Punjani2,3, Svetlana Altamentova2, Jonathon Chio2,3, Jian Wang2, Yann Godfrin1,4, Michael G. Fehlings2,5 1Axoltis Pharma, Lyon, France 2Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Canada 3Institute of Medical Science, University of Toronto, Toronto, Canada … Continued

NX210c PEPTIDE: A PROMISING DRUG CANDIDATE FOR BLOOD-BRAIN BARRIER REPAIR IN PARKINSON’S DISEASE Nicolas Rebergue1, Chris Greene2, Matthew Campbell2, Gwen Fewell3, Supriya Mahajan4, Damir Janigro4, Juliette Le Douce1, Sébastien Marie1, Annette Janus1, Yann Godfrin1,5 1Axoltis Pharma, Lyon, France 2Smurfit Institute of Genetics, Lincoln Place Gate, Trinity College Dublin, Dublin 2, Ireland 3SynVivo, Huntsville, USA 4Flocel, … Continued

NX210c PEPTIDE: A PROMISING DRUG CANDIDATE FOR NEUROPROTECTION IN PARKINSON’S DISEASE Juliette Le Douce1, Alexandre Henriques2, Noëlle Callizot2, Yann Godfrin1,3 1Axoltis Pharma, Lyon, France 2Neuro-Sys, Gardanne, France 3Godfrin Life-Sciences, Caluire-et-Cuire, France Objectives PD is characterized by the accumulation of α-synuclein and blood-brain barrier disruption, thereby contributing to the loss of dopaminergic neurons in the substantia … Continued

NX210c: subcommissural organ-spondin-derived peptide enhances behavioural functional recovery and tissue preservation in cervical traumatic spinal cord injury

A multi-properties peptide (NX210c) for the treatment of ALS

Subcommissural organ-spondin-derived peptide (NX210c) promotes glutamatergic receptor-related synaptic transmission and signaling in the mouse CNS